Why It Matters
McDermottPlus LLC filed a lobbying disclosure termination with the Preventive Medicine Research Institute (PMRI) on July 6, 2026, ending a representation that concluded on June 30. The LDA filing, which covers the second quarter of 2026, listed a filing amount of $20,000 for the engagement period.
The termination marks the end of advocacy work on behalf of PMRI, a research organization focused on disease prevention through lifestyle medicine. McDermottPlus had deployed a team of four lobbyists to handle the account, each bringing distinct congressional experience to the engagement.
By The Numbers
The termination represents a modest revenue loss for McDermottPlus. The total historical spending by PMRI with the firm remains undisclosed in available records.
McDermottPlus assembled a notable team for the PMRI lobbying client work. Josh Jorgensen, a Director at the firm, brought prior member experience with Sen. Mike Rounds (R-SD). Rodney Whitlock, a Vice President, contributed prior member experience with Rep. Charles Norwood (R-GA) and committee experience with the Senate Finance Committee. Debbie Curtis, a Principal, offered prior member experience with Rep. Fortney Pete Stark (D-CA) alongside committee experience with the House Ways and Means Committee. Julia Grabo, a lobbyist at the firm, provided prior member experience with Rep. Colin Z. Allred (D-TX)
Broader Context
The timing of the termination coincides with congressional activity focused on preventive medicine and healthcare reimbursement structures. The House Ways and Means Subcommittee on Health held a field hearing on April 14, 2026 titled "Modernized Health Care in Practice: Empowering Americans to Live Healthier Lives." At that hearing, Rep. Adrian Smith of Nebraska asked witnesses about challenges and opportunities for widespread investment in preventive medicine. A witness testified that Medicare reimbursement structures consistently fail to reward primary care providers for keeping patients healthy.
Congressional interest in preventive medicine research also surfaced in other forums. Rep. Michael Simpson of Idaho discussed the National Institute of Health's (NIH) preventive medicine research programs at a March 17, 2026, House Committee on Appropriations oversight hearing on the NIH. Simpson specifically discussed the National Institute of Dental and Craniofacial Research's use of epidemiology and preventive approaches.
Separately, concerns about research funding emerged during budget discussions. Sen. Tammy Baldwin of Wisconsin raised concerns about declining NIH research grant funding at an April 21, 2026, Senate Subcommittee on Departments of Labor, Health and Human Services, and Education hearing on FY2027 HHS budget estimates. Baldwin specifically raised concerns about declining funding at the National Cancer Institute.
No hearing statements in the past year contained a direct mention of PMRI by name, suggesting the organization did not face specific congressional scrutiny during this period.
The Bottom Line
No records of new lobbying firm engagements by PMRI have been identified in available disclosures, making the organization's current advocacy status unclear.
The team McDermottPlus assembled for PMRI work possessed relevant expertise for the policy landscape surrounding preventive medicine and healthcare reimbursement. Whitlock's Senate Finance Committee experience and Curtis's House Ways and Means Committee background positioned them to engage with the key committees addressing Medicare policy and healthcare financing. The combination of member-level relationships across both chambers provided potential access points for advocacy on preventive medicine issues.
The LDA filing 2026 termination occurred as Congress examined preventive medicine investment and research funding, suggesting the organization may have reassessed its advocacy priorities or resource allocation.
The termination represents one of several shifts in healthcare-focused lobbying representation, reflecting the fluid nature of client-firm relationships in the policy space.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article